New Alzheimer’s disease medication approved in Japan

25 Sep 2023
www.pharmaceutical-technology.com
Drug ApprovalPhase 3Clinical Result
New Alzheimer’s disease medication approved in Japan
Preview
Source: Pharmaceutical Technology
Jenna Philpott
New Alzheimer’s disease medication approved in Japan
Preview
Source: Pharmaceutical Technology
Japan is the second country to gain approval after the US gained traditional approval for the drug in July 2023. Credit: Ralf Liebhold via www.shutterstock.com.
Eisai and BioArctic have received approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb) in Japan, making it the second country to gain access to the treatment.
Leqembi is a monoclonal antibody that targets and reduces insoluble amyloid-beta (Aβ) forms in the brain. It is the first and only approved treatment that has demonstrated a reduction in the rate of disease progression in patients with Alzheimer’s.
Recommended Reports
New Alzheimer’s disease medication approved in Japan
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Aspirin in Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) GlobalData
New Alzheimer’s disease medication approved in Japan
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Mevidalen Hydroxybenzoate in Lewy Body Dementia GlobalData
View allCompanies IntelligenceEisai Co LtdBioArctic ABView all
The Japanese approval unlocked a milestone-based payment of EUR 17m ($18m) to BioArctic.
The approval is based on Phase III data from the Clarity AD trial (NCT03887455) led by Eisai that showed that treatment with Leqembi reduced clinical decline in patients by 27% at 18 months compared to the placebo.
The prescribing information for Leqembi includes a warning for amyloid-related imaging abnormalities (ARIAs), a concern for Alzheimer’s patients taking certain medication. Last week, BrainScope announced an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to pursue the development of a biomarker that could detect ARIAs in to reduce the number of magnetic resonance imaging (MRI) scans required for patients who suffered a concussion.
Leqembi was awarded a full traditional approval in the US in July 2023.
Co-founder of BioArctic and inventor of Leqembi Professor Lars Lannfelt said, in a statement to Pharmaceutical Technology, “The approval of Leqembi, first in the USA and now in Japan, is a paradigm-shifting step in the fight against Alzheimer’s disease.”
According to GlobalData, the AD market in Japan will be worth $957.7M in 2030, with Leqembi being the highest selling drug, generating $204.3 million in sales.
GlobalData is the parent company of Pharmaceutical Technology.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.